Compare Ford Motor Company (F) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs Medpace Holdings Inc — how do they compare? Ford Motor Company trades at $14.16 (market cap $56.50B), while Medpace Holdings Inc trades at $535.54 (market cap $15.11B). The key difference: Ford Motor Company is far larger — about 3.7× Medpace Holdings Inc's market cap, and Ford Motor Company pays a 4.23% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| F | MEDP | |
|---|---|---|
Market Cap | $56.50B | $15.11B |
Sector | Consumer Cyclical | Technology |
52-Week High | $17.44 | $620.59 |
52-Week Low | $10.82 | $308.88 |
Enterprise Value | $185.53B | $14.58B |
Dividend Yield | 4.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford (F) trades at $13.93, up 0.44% on the day, with a neutral technical outlook and mixed fundamental signals. The company reported a net loss of $8.18 billion in 2025 despite revenue growth to $187.27 billion, reflecting margin pressure. Recent news highlights labor agreements, EV initiatives, and a 4%+ dividend yield. Analyst consensus is a $15.00 price target with a Hold-heavy rating distribution.
The stock presents a value opportunity with low P/E and P/S ratios, but significant risks include persistent net losses, high debt levels, and competitive pressures in the EV transition. Upside depends on execution of cost controls and successful new product launches, particularly in electric vehicles.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
